Chiesi Farmaceutici S.p.A.: alpha-Mannosidosis trials
The registry lists 12 alpha-Mannosidosis studies with Chiesi Farmaceutici S.p.A. as lead sponsor. 2 are open to participants now and 0 have results posted.
Phase 1 1Phase 2 3Phase 3 5No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3RecruitingNCT06184503
- Expanded Access to Velmanase AlfaAvailableNCT04959240
- Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha MannosidosisWithdrawnNCT04031066Phase 3
- Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-MannosidosisCompletedNCT02998879Phase 2
- Evaluation of Long-term Efficacy of Treatment With LamazymCompletedNCT02478840Phase 3
- Lamazym Aftercare StudyCompletedNCT01908725Phase 3
- Lamazym Aftercare Study FR Designed to Provide Treatment for French PatientsCompletedNCT01908712Phase 3
- A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-MannosidosisCompletedNCT01681953Phase 3
- Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-MannosidosisCompletedNCT01681940Phase 2
- Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosisStatus unknownNCT01285700Phase 2
- Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosisCompletedNCT01268358Phase 1
- The Natural History of Alpha-MannosidosisCompletedNCT00498420